Psych CASC / OSCE · Consultation-liaison psychiatry
Explaining PD psychosis, agonist ICD risk, and treatment choices to a spouse — CASC communication station
MRCPsych/FRANZCP-style station: explain PD psychosis and ICD, why high-potency antipsychotics are dangerous, rationale for DRT review and low-dose clozapine or pimavanserin, and safe shared plan.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar. Neurology remains involved. You meet the spouse alone first.[1]
Candidate instructions. Explain PD psychosis in plain language (not primary schizophrenia). Explain that some Parkinson medicines — especially dopamine agonists — can drive impulse control problems such as gambling. Explain why drugs like haloperidol are dangerous in PD, and why low-dose clozapine (with blood tests) or pimavanserin (if available) differ. Agree a plan that does not stop all Parkinson medicines abruptly. Address safety and follow-up. Avoid inventing legal section numbers.[2][3][5]
Candidate scenario
Spouse: "He sees people in the garden. Your Parkinson pills made him gamble our savings. If you give him a schizophrenia tablet he will freeze solid. Stop every tablet and send him home tonight. I will not allow blood tests." Notes confirm visual hallucinations, pramipexole-related gambling, depression screen positive, no acute infection.[1][2]
Marking domains
Empathy without defensiveness; accurate plain-language model of PD psychosis; clear agonist–ICD link; balanced DRT discussion (review/reduce, not abrupt total stop); explain clozapine low-dose evidence and monitoring or pimavanserin mechanism/access; safety and not unsafe same-day discharge if risk remains; shared neurology–psychiatry plan and understanding check.[1][3][4]
Reveal assessor key
Open. Acknowledge fear and financial trauma: "Seeing people that are not there, and the gambling, would frighten any family. You are right to want answers." [1][2]
Explain psychosis. "This pattern is often called Parkinson disease psychosis. Many people see people or animals, especially later in the day. It is a known complication of the disease and its treatments — it does not automatically mean lifelong schizophrenia." [1]
Explain ICD. "Dopamine agonist tablets such as pramipexole can, in some people, drive impulse control problems — gambling, shopping, or sexual behaviour changes. Reducing or stopping that agonist carefully with the neurology team is a key step, with safeguards around money." [2]
About stopping everything. "We will review and simplify medicines with neurology. But stopping all Parkinson medicines suddenly is unsafe — he could become very stiff, immobile, or swallow poorly. Changes must be planned." [5]
About antipsychotics. "Some strong dopamine-blocking medicines like haloperidol can make Parkinson stiffness much worse — we avoid those. If hallucinations remain dangerous after medicine review, options with better PD evidence include very low-dose clozapine (different doses than schizophrenia, but blood tests are essential for safety) or, where available, pimavanserin, which works on serotonin pathways rather than blocking dopamine the same way." [3][4]
Home tonight. "Going home depends on safety, settling of risk, and a clear plan — not only preference. We want neurology and mental health follow-up, and a plan if hallucinations or gambling urges return." [1][5]
Close. Summarise, invite questions, offer written information, introduce neurology contact, document. [5]
References
- [1]Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group Mov Disord, 2007.PMID 17266092
- [2]Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol, 2010.PMID 20457959
- [3]Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med, 1999.PMID 10072410
- [4]Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Lancet, 2014.PMID 24183563
- [5]Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review Mov Disord, 2019.PMID 30653247